The FDA provides details on the breakdown for the new Office of In Vitro Diagnostics and Radiological Health, formerly known as the Office of In Vitro Diagnostic Device Evaluation and Safety.
The FDA this week provided updates on the revamped Office of In Vitro Diagnostics & Radiological Health, formerly known as the Office of In Vitro Diagnostic Device Evaluation and Safety.
The Center for Devices & Radiological Health subsection will oversee in-home and laboratory diagnostic tests, radiological medical devices and radiation-emitting non-medical products, and will be responsible for implementing the Mammography Quality Program established federally in 1992.
The FDA further broke down the various sections with the ORI, defining their duties as follows:
Division of Chemistry and Toxicology Devices (DCTD)
- General chemistry tests
- Specialized chemistry tests including neonatal biochemical screening tests, endocrine tests, and tests for women's health
- Drug of abuse tests
- Therapeutic drug monitoring tests
- Minimally invasive and non-invasive tests
Division of Immunology and Hematology Devices (DIHD)
- Hematology, pathology, flow cytometry, and coagulation tests
- Tests for immunological disease
- Tumor marker (cancer detection) tests
- Genetic disorder (heritable somatic mutations) tests
Division of Microbiology Devices (DMD)
- Detection of microorganisms (bacteria, fungi, mycobacteria, viruses) by chemical, immunological, and nucleic acid amplification methods
- Biothreat agents
- New and emerging infectious diseases
Division of Radiological Health (DRH)News Well, 510(k), Food & Drug Administration (FDA), Pre-Market Approval (PMA), Regulatory/Compliance
Pulmonx taps former Asthmatx CEO Glen French to be its new chief executive.
Here's a look at some of the top legal news stories for medical device companies this week: InSightec...
The U.S. says it hammered out a deal with China to speed American-made medical devices and drugs to...
Delcath Systems adds 2 German research centers to a Phase II clinical trial of its Chemosat...
The FDA awards priority review status to Cohera Medical's surgical sealant Sylys because the product...